Biohaven Pharmaceuticals, Inc.
Clinical trials sponsored by Biohaven Pharmaceuticals, Inc., explained in plain language.
-
New hope for stubborn OCD? major trial tests Add-On pill
Disease control CompletedThis study tested whether adding a new drug called troriluzole to a person's current OCD medication could help reduce symptoms better than adding a placebo (a dummy pill). It involved 456 adults whose OCD symptoms were not well-controlled by their standard medication alone. The g…
Phase: PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for stubborn OCD? Add-On drug put to the test
Disease control CompletedThis study tested whether adding a new drug called troriluzole could help adults with moderate-to-severe OCD who were still struggling despite taking standard antidepressant medications. Over 400 participants were randomly assigned to receive either troriluzole or a placebo (a du…
Phase: PHASE2, PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug trial aims to slow debilitating genetic movement disorder
Disease control CompletedThis study tested whether a drug called troriluzole could help control the symptoms of spinocerebellar ataxia (SCA), a group of rare, inherited disorders that cause worsening problems with coordination and balance. For 8 weeks, 141 adults with SCA received either the drug or a pl…
Phase: PHASE2, PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC